Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 565131 | ISIN: DK0010272202 | Ticker-Symbol: GE9
Tradegate
06.06.25 | 14:35
193,00 Euro
+0,86 % +1,65
1-Jahres-Chart
GENMAB A/S Chart 1 Jahr
5-Tage-Chart
GENMAB A/S 5-Tage-Chart
RealtimeGeldBriefZeit
193,15193,2515:33
193,05193,1515:33

Aktuelle News zur GENMAB Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiLeerink Partners raises Genmab stock price target to $32 from $2921
GENMAB Aktie jetzt für 0€ handeln
DiASCO25: Genmab's Rina-S en route to 'blockbuster potential' amid further positive data10
DiGenmab macht Fortschritte mit niedrigerer Dosis von Rina-S in Studien zu Endometriumkarzinom4
DiGenmab advances with lower dose of Rina-S in endometrial cancer trials5
DiWhy Genmab Stock Smashed It on Monday6
MoGenmab A/S: Genmab Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial314New data showed that rinatabart sesutecan (Rina-S) 100 mg/m2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete responses (CR), and median duration of response...
► Artikel lesen
MoGenmab A/S: Transactions in Connection with Share Buy-back Program6
27.05.GENMAB A/S - 6-K, Report of foreign issuer7
26.05.Genmab A/S: Transactions in Connection with Share Buy-back Program5
23.05.Endometrial cancer data on Genmab's Elahere rival beat forecast, fueling push into phase 36
22.05.Genmab A/S: Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting436First presentation of results from Phase 1/2 clinical trial of investigational rinatabart sesutecan (Rina-S) in patients with recurrent/advanced endometrial cancer Presentation of long-term...
► Artikel lesen
22.05.Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise159The share capital of Genmab A/S has been increased. The admittance to trading and official listing will take effect as of 23 May 2025 in the ISIN below. ISIN: DK0010272202 Name: Genmab Volume...
► Artikel lesen
21.05.J&J, Genmab win FDA AdCom backing for multiple myeloma therapy8
20.05.Genmab A/S: Capital Increase in Genmab as a Result of Employee Warrant Exercise3
19.05.GENMAB A/S - 6-K, Report of foreign issuer2
19.05.Genmab A/S: Transactions in Connection with Share Buy-back Program4
14.05.Genmab A/S: Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY) Development Program at the 2025 European Hematology Association (EHA) Congress374Data from 14 abstracts highlight the depth, breadth, and strength of Genmab's comprehensive epcoritamab development program across multiple patient populations and treatment settings Genmab...
► Artikel lesen
14.05.Genmab stock price target cut to $35 at H.C. Wainwright20
12.05.GENMAB A/S - 6-K, Report of foreign issuer2
12.05.Genmab A/S: Transactions in Connection with Share Buy-back Program5
Weiter >>
120 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1